Abstract
The effect of 1,25-dihydroxyvitamin D3, analog C (1,25-(OH)2-16-en-23-yn-26,27-F6-vitamin D3), 9-cis retinoic acid, and all-trans retinoic acid on the growth and expression of EGFR in MCF7, T47D, BT474, and BT549 breast cancer cells was examined. Significant growth inhibition was noted in MCF7, T47D, and BT474 cells by 8 days of treatment, while BT549 cells showed none. MCF7, T47D, and BT549 cells treated with 1,25-dihydroxyvitamin D3 demonstrated a 50% decrease in EGFR mRNA within 2 h which was sustained to 72 h, while BT474 cells demonstrated a 200–500% increase. EGFR protein levels correlated with these mRNA changes in BT474 and BT549 cells. Measurement of mRNA stability in vitamin D treated BT474 cells indicated that there was no change in EGFR mRNA half-life. Transfection of an EGFR promoter containing reporter plasmid demonstrated vitamin D induced changes in reporter gene activity that paralleled the changes observed in EGFR mRNA and protein. Electrophoretic mobility shift assays using a putative vitamin D response element within this region of the EGFR promoter demonstrated specific VDR binding. These results indicate that the vitamin D effect on EGFR expression in breast cancer cells has a transcriptional component likely mediated through a vitamin D responsive promoter sequence. They also suggest that growth inhibition and EGFR down-regulation by vitamin D and retinoids may be related events in some breast cancer cells, but not in all.
Similar content being viewed by others
References
Rajkumar T, Gullick WJ: The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 29: 3–9, 1994
Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, Evans SR: Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 31: 191–202, 1994
Looi LM, Cheah PL: C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of the breast relates to high histological grade and loss of estrogen receptor protein. Malays J Pathol 20: 19–23, 1998
Harris AL: What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer? Breast Cancer Res Treat 29: 1–2, 1994
Sainsbury J, Farndon J, Needham G, Malcolm A, Harris A: Epidermal growth factor receptor status as a predictor of early recurrence of and death from breast cancer. Lancet I: 1398–1402, 1987
Chrysogelos SA, Dickson RB: EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 29: 29–40, 1994
Ulrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203–212, 1990
Jardines L, Weiss M, Fowble B, Green M: Neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 61: 268–282, 1993
Davidson NE, Gelmann EP, Lipmann ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216–223, 1987
DiFiore P, Pierce J, Fleming T, Hazon R, Ulrich A, King CR, Schlessinger J, Aaronson S: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH3T3 cells. Cell 51: 1063–1070, 1987
Liu YE, Lupu R, Kern FG: Characterization of MCF7 breast carcinoma cells singly or doubly transfected with c-erbB2 and EGFR. Proc AARC 33: 368, 1992
Agthoven TV, Agthoven TLAV, Portengen H, Foekers JA, Dorsse LCJ: Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52: 5082–5088, 1992
Baselga J, Medelsohn J: The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29: 157–138, 1994
Clark AJL, Ishii S, Richert N, Merlino GT, Pastan I: Epidermal growth factor regulates the expression of its own receptor. Proc Natl Acad Sci USA 82: 8374–8378, 1985
Desprez PY, Poujol D, Falette N, Lefebvre NF, Saez S: 1,25-dihydroxyvitamin D3 increases epidermal growth factor gene expression in BT-20 breast carcinoma cells. Biochem Biophys Res Comm 176: 1–6, 1991
Prasad KN, Edwards-Prasad J, Kumar S, Meyers A: Vitamins regulate gene expression and induce differentiation and growth inhibition in cancer cells. Their relevance in cancer prevention. Arch Otolaryngol Head Neck Surg 119: 1133–1140, 1993
Welsh J, VanWeelden K, Flanagan L, Byrne I, Nolan E, Narvaez CJ: The role of vitamin D3 and antiestrogens in modulating apoptosis of breast cancer cells and tumors. Subcell Biochem 30: 245–270, 1998
Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfiled AE: 1 alpha,25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ Res 87: 214–220, 2000
Hansen CM, Frandsen TL, Brunner N, Binderup L: 1 alpha,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 12: 195–202, 1994
Chouvet C, Vicard E, Devonec M, Saez S: 1,25-dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF7, BT-20). J Steroid Biochem 24: 373–376, 1986
Koga M, Sutherland RL: Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation. J Steroid Biochem Mol Biol 39: 455–460, 1991
Zheng ZS, Polakowska R, Johnson A, Goldsmith LA: Transcriptional control of epidermal growth factor receptor by retinoic acid. Cell Grow Diff 3: 255–232, 1992
Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-pheno-chloroform extraction. Anal Biochem 162: 156–159, 1987
Laborda J: 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucl Acids Res 19: 3998, 1991
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248–254, 1976
Salinovich O, Montelaro RC: Reversible staining and peptide mapping of proteins transferred to nitrocellulose after separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Analytical Biochem 156: 341–347, 1986
Dignam JD, Lebovitz RM, Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucl Acids Res 11: 1475–1489, 1983
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: the second decade. Cell 83: 835–839, 1995
Roman SD, Clarke CL, Hall RE, Alexander IE, Sutherland RL: Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res 52: 2236–2242, 1992
Shao ZM, Sheikh MS, Chen JC, Kute T, Aisner S, Schnaper L, Fontana JA: Expression of the retinoic acid nuclear receptors (RARs) and retinoid X receptor genes in estrogen receptor positive and negative breast cancer. Int J Oncol 4: 859–8563, 1994
Zhou JY, Norman AW, Akashi M, Chen DL, Uskokovic MR, Aurrecoehea JM, Dauben WG, Okamura WH, Koeffler HP: Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 78: 75–82, 1991
MacDonald PN, Dowd DR, Nakajima S, Galligan MA, Reeder MC, Haussler CA, Ozato K, Haussler MR: Retinoid X receptors stimulate and 9-cis retinoic acid inhibits 1,25-dihydroxyvitamin D3-activated expression of the rat osteocalcin gene. Mol Cell Biol 13: 5907–5917, 1993
DeLuca HF, Zierold C: Mechanisms and functions of vitamin D. Nutr Rev 56: S54–S75, 1998
Fridovich-Keil JL, Gudas JM, Bryan IB, Pardee AB: Improved expression vectors for eukaryotic promoter/enhancer studies. BioTechniques 11: 572–579, 1991
Umesono K, Murakami KK, Thompson CC, Evans RM: Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65: 1255–1266, 1991
Ozono K, Liao J, Kerner SA, Scott RA, Pike JW: The vitamin D-responsive element in the human osteocalcin gene. J Biol Chem 265: 21881–21888, 1990
Demay MB, Gerardi JM, DeLuca HF, Kronenberg HM: DNA sequences in the rat osteocalcin gene that bind the 1,25-dihydroxyvitamin D3 receptor and confer responsiveness to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 87: 369–373, 1990
Noda M, Vogel RL, Craig AM, Prahl J, DeLuca HF, Denhardt DT: Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phospoprotein 1 (Spp-1 or osteopontin.). Proc Natl Acad Sci USA 87: 9995–9999, 1990
Lippman SM, Kessler JF, Meyskens FL: Retinoids as preventive and therapeutic anticancer agents (part 1). Cancer Treat Rep 71: 391–405, 1987
Hunter DJ, Manson JE, Colditz GA, Stampfer MJ. Rosner B, Hennekens CH, Speizer FE, Wilett WC: A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med 329: 234–240, 1993
Blot WJ, Fraumeni JF, Stone BJ: Geographic patterns of breast cancer in the United States. JNCI 59: 1407–1411, 1977
Gorham ED, Garland CF, Garland FC: Acid haze air pollution in breast and colon cancer mortality in 20 Canadian cities. Can J Public Health 80: 96–100, 1989
Garland FC, Garland CF, Gorham ED, Young JF: Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 19: 614–622, 1990
Gorham ED, Garland FC, Garland CF: Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 19: 820–824, 1990
Garland FC, Garland CF, Gorham ED: Calcium and vitamin D: their potential roles in colon and breast cancer prevention. Ann NY Acad Sci 889: 107–119, 1999
Haddad JG, Hahn TJ: Natural and synthetic sources of circulating 25-hydroxyvitamin D in man. Nature 244: 515–517, 1973
Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA, Hulka BS: Association between low levels of 1,25-dihydroxyvitamin D3 and breast cancer risk. Public Health Nutr 2: 283–291, 1999
Bower M, Colston KW, Stein RC, Hedley A, Gazet J-C, Ford HT, Coombes RC: Topical calcipotriol treatment in advanced breast cancer. Lancet 337: 701–702, 1991
Colston KW, Berger U, Coombes RC: Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1(8631): 188–191, 1989
Sheikh MS, Shao Z-M, Chen J-C, Hussain A, Jetten AM, Fontana JA: Estrogen receptor-negative breast cancer cells transfected with the estrogen receptor exhibit increased RARa gene expression and sensitivity to growth inhibition by retinoic acid. J Cell Biochem 53: 394–404, 1993
Welsh J, Wietzke J, Zinser G, Smyczek S, Romu S, Tribble E, Welsh J, Byrne B, Narvaez C: Impact of the vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 83: 85–92, 2003
Bortman P, Folgueira M, Katayama M, Snitcovsky I, Brentani M: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells-a mini review. Braz J Med Biol Res 35: 1–9, 2002
Farach-Carson MC, Sergeev I, Norman AW: Nongenomic actions of 1,25-dihydroxyvitamin D3 in rat osteosarcoma cells: structure-function studies using ligand analogs. Endocrinology 129: 1876–1884, 1991
Nemere I, Norman AW: Steroid hormone actions at the plasma membrane: induced calcium uptake and exocytotic events. Mol Cell Endocrinol 80: C165–C169, 1991
Sorensen AM, Bowman D, Baran DT: 1α,25-dihydroxyvitamin D3 rapidly increases nuclear calcium levels in rat osteosarcoma cells. J Cell Biochem 52: 237–242, 1993
Lieberherr M: Effects of vitamin D3 metabolites on cytosolic free calcium in confluent mouse osteoblasts. J Biol Chem 262: 13168–13173, 1987
Grosse B, Bourdeau A, Lieberherr M: Oscillation in inositiol 1,4,5-triphosphate and diacylglycerol induced by vitamin D metabolites in confluent mouse osteoblasts. Bone Min Res 8: 1059–1069, 1993
Jeni LG, Lian JB, Stein GS, Baran DT: 1?,25-dihydroxyvitamin D3-induced changes in intracellular pH in osteoblast-like cells modulate gene expression. J Cell Biochem 53: 234–239, 1993
Laird AD, Shalloway D: Oncoprotein signalling and mitosis. Cell Signal 9: 249–255, 1997
Codero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl P, Barbieri MA, Dusso A: 1,25-dihydroxyvitamin D downregulates cell membrane growth and nuclear-growth promoting signals by the epidermal growth factor receptor. J Biol Chem 277: 38965–38971, 2002
Koga M, Eisman JA, Sutherland RL: Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells. Cancer Res 48: 2734–2739, 1988
Falette N, Frappart L, Lefebvre MF, Saez S: Increased epidermal growth factor receptor level in breast cancer cells treated by 1,25-dihydroxyvitamin D3. Mol Cell Endo 63: 189–198, 1989
Yarden RI, Wilson MA, Barth M, Chrysogelos SA: The role of estrogen in the regulation of EGFR expression. In: Lichtner RB, Harkins RN (eds) Ernest Schering Research Foundation Workshop 19: EGF Receptor in Tumor Growth and Progression. Springer Scientific Publishers, Berlin, 1996, pp 129–154
Pike JW: Vitamin D3 receptors: structure and function in transcription. Annu Rev Nutr 11: 189–216, 1991
Gonzales EA, Disthabanchong S, Kowalewski R, Martin K: Mechanisms of regulation of egf receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells. Kidney Int 61: 1627–1634, 2002
Haley J, Whittle N, Bennet P, Kinchington D, Ulrich A, Waterfield M: The human egf receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res 1: 375–396, 1987
Johnson AC, Ishii S, Jinno Y, Pastan I, Merlino GT: Epidermal growth factor gene promoter. Deletion analysis and identification of nuclear protein binding sites. J Biol Chem 263: 5693–5699, 1988
Kageyama R, Pastan I: Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell 59: 815–825, 1989
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McGaffin, K.R., Acktinson, L.E. & Chrysogelos, S.A. Growth and EGFR Regulation in Breast Cancer Cells by Vitamin D and Retinoid Compounds. Breast Cancer Res Treat 86, 55–73 (2004). https://doi.org/10.1023/B:BREA.0000032923.66250.92
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000032923.66250.92